Cefepime vs. conventional combination therapy for PD-associated peritonitis

Intraperitoneal cefepime monotherapy is noninferior to conventional combination therapy for resolution of continuous ambulatory peritoneal dialysis-associated peritonitis.

A new randomized controlled study evaluated whether intraperitoneal (IP) cefepime monotherapy is noninferior to combination regimens for continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis. Results showed that IP cefepime monotherapy was noninferior to conventional combination therapy for resolution of CAPD-associated peritonitis at day 10 and may be a reasonable alternative first-line treatment.

Find out more here